<DOC>
	<DOCNO>NCT01519089</DOCNO>
	<brief_summary>The main objective study evaluate long term safety CP-690,550 patient treat moderate severe plaque psoriasis and/or psoriatic arthritis . This study also compare efficacy two oral dos CP-690,550 ( 5 mg BID 10 mg BID ) 16 week treatment .</brief_summary>
	<brief_title>A Long Term Study To Evaluate The Safety , Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Are 20 year old consider candidate systemic phototherapy . [ Moderate Severe Plaque Psoriasis ] Diagnosed least 12 month . Have Psoriasis Area Severity Index ( PASI ) score 12 plaque type psoriasis cover least 10 % body surface area ( BSA ) . [ Psoriatic Arthritis ] Diagnosed least 6 month . Meet CASPAR ( classification criterion Psoriatic Arthritis ) criteria screen ; Have active arthritis ( ≥3 tender/painful joint motion ≥3 swell joint ) , active plaque psoriasis least 2 cm diameter . Nonplaque drug induce form psoriasis Can discontinue current oral , injectable topical therapy psoriasis/psoriatic arthritis discontinue phototherapy ( PUVA UVB ) uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>chronic</keyword>
	<keyword>severe</keyword>
	<keyword>moderate</keyword>
	<keyword>treatment</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
</DOC>